Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634825 · ClinicalTrials.gov registry record · Phase 2
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
A Phase 2 study, sponsored by MacroGenics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT04634825: Clinical Trial Phase 2 study, sponsored by MacroGenics.
NCT04634825 is a Phase 2 study that was terminated before completion, run by MacroGenics. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04634825, a Phase 2 study, was terminated before completion, sponsored by MacroGenics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Primary Outcome
Investigator-assessed ORR. defined as the percentage of patients in the response evaluable population who achieve the best overall response of complete response (CR) or partial response (PR),per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.. CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions
Interventions
- BIOLOGICAL Retifanlimab
- BIOLOGICAL Tebotelimab
- BIOLOGICAL Enoblituzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 2 |
Why NCT04634825 stopped before completion
NCT04634825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which Retifanlimab is the first listed.
NCT04634825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04634825 about?
NCT04634825 is a clinical study titled "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer". This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
What is the current status of trial NCT04634825?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2021-03-17. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT04634825?
The interventions under investigation include: Retifanlimab (BIOLOGICAL), Tebotelimab (BIOLOGICAL), Enoblituzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04634825?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04634825's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI